Nivolumab as first line monotherapy for advanced non-small cell lung cancer: could we replace first line chemotherapy with immunotherapy?

Gelijkaardige items

• Nivolumab Monotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer
  door: Gettinger, Scott, et al.
  Gepubliceerd in: (2016)
• Nivolumab in Combination With Platinum‐Based Doublet Chemotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer
  door: Rizvi, Naiyer A., et al.
  Gepubliceerd in: (2016)
• First-line immunotherapy in advanced non-small-cell lung cancer
  door: Vanita Noronha, et al.
  Gepubliceerd in: (2019-01-01)
• Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab vs. Chemotherapy as First-Line Therapy in Advanced Non-Small Cell Lung Cancer
  door: Huabin Hu, et al.
  Gepubliceerd in: (2020-09-01)
• Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab vs. Chemotherapy as First-Line Therapy in Advanced Non-Small Cell Lung Cancer
  door: Hu, Huabin, et al.
  Gepubliceerd in: (2020)